Vetanic Co., Ltd.

Advanced veterinary medicine using iPS cells to many companion animals


Establishment Date
January 2021
Research and development, manufacture and sale of products such as regenerative medicine for animals, and research and development, manufacture and sale of reagents related to regenerative medicine
President and CEO Akinori Mochizuki

Point of KII view

Vetanic, which succeeded in producing the world's only canine iPS cells suitable for clinical application, hopes to promote the spread of veterinary regenerative medicine by developing various products such as MSC and other iPS cell-derived regenerative medicine. I will.

KII growth support

Funding lead, business strategy support, business structure construction support, key human resources recruitment support, public relations support, selection of business partner candidates and negotiation support